Strategic report
Annual Report and Financial Statements 2024
14
Process Update and Portfolio Alignment
After three years of testing shareholders’ patience
with returns that haven’t been good enough, in the
second half of 2024, we recognised the necessity to
thoroughly review the ‘why’ and ‘how’ of what we do.
fi
of recent macroeconomic headwinds, the scale of
underperformance hinted at systematic errors that
we were keen to understand better and remedy.
We are grateful for the wholehearted support
and valuable collaboration with the Board while
undertaking this important work.
We’d stress that the ‘why’ remains immovable. EWIT
looks to invest in tomorrow’s winners while they are
still early in their journey. Our philosophy is based
on the fundamental belief that problem‑solving
is an inherent human trait. Over time, technology
and science have led to economic prosperity and
fi
By investing in technology‑led innovation, we are
backing human ingenuity and progress. We look
for growth, entrepreneurial mindset and innovative
solutions. And nowhere is this more present than in
the small companies universe, a place of potential
and possibility. Notably, the review underscored that
our approach remains a differentiated means to
access this vibrant opportunity set, particularly with
the resultant access to unique private businesses.
Yet, the “how” is iterative, with insights building over
time. As a management team, we consistently learn,
hypothesise, test, and interpret results. As a normal
course of action, you should expect us to gradually
enhance our processes to achieve better results.
As painful as it is, a period like that we’ve just been
in can often be the richest in learning, bringing into
fl
Based on lessons from this period, we’ve made
fi
bolstering the investment decision‑making structure,
addressing the strategy’s key risk factor with a new
portfolio construction framework, and strengthening
fi
to improve our hold discipline and deliver a better
spread of exposures within the portfolio regarding
fi
We’re excited that these enhancements will create
fi
pockets of the portfolio. The team will be made to
consider the marginal holding in areas of industrial
concentration and the earliest stage, most volatile
assets, prompting us to delve more deeply into the
team’s relative conviction levels. In short, these
enhancements should create a better, more robust
investment process to help us make a higher
proportion of value‑accretive investment decisions.
fi
progress implementing these adjustments, moving
around 8% of the portfolio towards alignments.
This entailed reducing exposure to several of our
healthcare and software companies. Simultaneously,
we exited several positions where a commercial
fl
conviction in a successful outcome has diminished
*
.
Accordingly, the number of portfolio holdings has
come down meaningfully over the last year. We are
fi
may reduce that further.
It’s worth highlighting that idea generation has
continued apace. We’ve sought ideas from a broad
range of geographies, sectors, and maturity stages
to support the rebalancing. A few examples include:
Silergy, one of China’s leading analogue
semiconductor companies. The manufacture
of analogue chips continues to be an industry
dominated by US companies. As the largest, most
reputable local player, Silergy is well‑placed to
fi
US‑based Rx Sight makes adjustable intra‑ocular
lenses, allowing doctors to customise patients’
vision after cataract surgery, enabling better vision
without glasses. Its small market share leaves a
runway for growth in the US and internationally.
Britain’s Raspberry Pi, the maker of the
eponymous low‑cost, compact single‑board
computers and computing modules, should
experience substantial growth over the coming
year as these get embedded and become the
“brains” in IoT factories and Edge AI products.
dLocal is a Uruguayan payment processor that
helps global merchants do business in emerging
markets. Payments tend to be local in these
markets, credit card fraud is rampant, and the
regulatory and tax landscape is constantly
evolving. Growth should remain strong as the
penetration of e‑commerce across these markets
continues to increase.
* Sutro Biopharma, Ilika, LivePerson Inc, Codexis, Cosmo Pharmaceuticals, EverQuote Inc, Cellectis, Avacta and Beam.